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Why read this summary?
Drug misuse is an increasing problem that not only impairs the physical and mental health of people who misuse drugs but also negatively affects their families and wider society (for example, in its association with crime). Recently expanded drug services in the United Kingdom involve general practitioners to a considerable degree, who care for at least a third of opioid misusers in treatment. Many clinicians remain pessimistic, however, about the possible benefits of any treatment and how to engage drug users in treatment. 1 This article summarises two new National Institute for Health and Clinical Excellence (NICE) guidelines that identify the most effective, safe detoxification regimens for primary and secondary care, the most cost effective psychosocial interventions, and effective ways to promote patient engagement.
2 3 recommendations NICE recommendations are based on systematic reviews of best available evidence. When minimal evidence is available, a range of consensus techniques is used to develop recommendations. In this summary, recommendations derived primarily from consensus techniques are indicated with an asterisk (*).
opioid detoxification

General principles
For all patients who are opioid dependent and have expressed an informed choice to become abstinent, services should:
• Offer detoxification as a readily available and effective treatment option; • Provide detailed information about detoxification and the associated risks, including: -The physical and psychological aspects of opioid withdrawal, including the duration and intensity of symptoms -How such symptoms may be managed, including non-pharmacological approaches -The loss of opioid tolerance after detoxification, and the ensuing increased risk of overdose and death from illicit drug use (this risk may be potentiated by alcohol or benzodiazepine use) - weeks, two tests a week for the next three weeks, and once weekly thereafter until stability is achieved); urine analysis is the preferred method of testing, but oral fluid tests may be used as an alternative.
• For those at risk of physical comorbidity from drug misuse, consider material incentives (such as shopping vouchers of up to £10 in value) on a one-off basis or over a limited duration, contingent on concordance with specified harm reduction activities, particularly for: -Hepatitis B or C and HIV testing -Hepatitis B immunisation -Tuberculosis testing.
Overcoming barriers
In recent years drug treatment has focused on harm reduction rather than abstinence as a goal, but the evidence on detoxification makes clear that abstinence is an effective treatment option. Furthermore, although psychosocial interventions for drug misuse are not well developed, the evidence suggests that they can bring real benefits, in part through increasing the value of currently used treatments. Contingency management has been little used in the UK, is open to misunderstanding by clinicians and the general public, and will require considerable training of staff and service development if it is to be introduced appropriately and effectively. It involves a new way of thinking, with the use of positive incentives instead of negative approaches such as the withholding of treatment. The evidence is that, particularly with this patient population, behaviour can be positively shaped with incentives, whereas threats and punishment have little influence. Overseas trials involving more than 5000 patients across more than 25 studies have consistently shown that such an approach reduces illicit drug use, is cost effective, and improves engagement in harm reduction and treatment programmes.
To tackle these challenges, it is proposed that the National Treatment Agency in the UK will establish a network of demonstration centres, which will develop Further information about the guidance Methods The guidelines were developed according to NICE guideline methodology (see www.nice.org.uk/page.aspx?o=114219) by the National Collaborating Centre for Mental Health. The collaborating centre convened a development group of clinicians and patient and carer representatives for each guideline to oversee the work and develop the recommendations. The groups conducted extensive systematic reviews of the clinical and economic literature and assessed the quality of this literature. The guidelines went through an external consultation with stakeholders. The development groups assessed the comments, reanalysed the data where necessary, and modified the guidelines. NICE has produced four different versions of each guideline: a full version; a quick reference guide (which combines both guidelines); a version known as the "NICE guideline" that summarises the recommendations; and a version for patients and the public. All these versions are available from the NICE website (see www.nice.org. uk/CG051 and www.nice.org.uk/CG052). Future updates of the guidelines will be produced as part of the NICE guideline development programme.
on 7 September 2007 bmj.com Downloaded from Practice materials to support a phased implementation of contingency management, support staff training and supervision programmes, and assess the relative value of different incentive systems.
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Anti-RNA polymerase antibodies are strongly associated with scleroderma renal crisis, and we consider Four weeks ago we described the case of a 46 year old woman who presented with possible miscarriage, severe hypertension, acute renal failure, pulmonary oedema, microangiopathic haemolytic anaemia, and seizures (BMJ 2007; 334:1372. 30 June) . The diagnoses we considered are malignant hypertension, intrinsic renal disease, a primary microangiopathic process-such as haemolytic uraemic syndrome or thrombotic thrombocytopenic purpura, or eclampsia with HELLP syndrome. She was started on intermittent haemodialysis, an angiotensin converting enzyme inhibitor, and plasma exchange (BMJ 2007; 335:44. 7 July) . A magnetic resonance imaging scan of the brain showed posterior leucoencephalopathy consistent with hypertensive encephalopathy.
Her platelet count, metabolic abnormalities, and breathlessness improved and she had no further seizures. At one week she was well but remained dependant on dialysis. Bisoprolol and amlodipine were added to control her blood pressure.
Renal Doppler ultrasound showed poor renal perfusion so we performed angiography to exclude renovascular disease. This showed normal renal vessels (fig 1) , suggesting a microangiopathic infrarenal process.
Renal biopsy demonstrated florid myxoid intimal thickening in interlobular arteries (fig 2) , widespread acute tubular damage, and glomerular ischaemic changes. There was little thrombotic change to suggest haemolytic uraemic syndrome or thrombotic thrombocytopenic purpura. These appearances are consistent with a diagnosis of malignant hypertension or scleroderma renal crisis.
The table summarises the other investigations and blood tests. These were negative except for a strongly positive speckled antinuclear antibody at a titre of more than 1/1000. The staining pattern was consistent with
